Fieldpoint Private Securities’s NovoCure NVCR Stock Holding History

Fieldpoint Private Securities’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$56K	Sell	801 -2	-0.2%	-$151	0.02%	461
2022 Q1	$67K	Hold	803	–	–	0.01%	510
2021 Q4	$60K	Hold	803	–	–	0.01%	553
2021 Q3	$93K	Hold	803	–	–	0.02%	429
2021 Q2	$114K	Sell	803 -211	-21%	-$41K	0.02%	392
2021 Q1	$134K	Sell	1,014 -239	-19%	-$37.8K	0.03%	353
2020 Q4	$217K	Buy	+1,253	New	+$171K	0.05%	274
2020 Q2	–	Sell	-3,393	Closed	-$229K	–	281
2020 Q1	$229K	Buy	3,393 +1,626	+92%	+$129K	0.09%	214
2019 Q4	$148K	Buy	+1,767	New	+$143K	0.04%	297

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fieldpoint Private Securities's NVCR Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its NovoCure (NVCR) stake by 0.25% in Q2 2022, selling an estimated $151 and leaving 801 shares worth $56K. The position accounts for 0.02% of the portfolio, ranked #461.

Fieldpoint Private Securities first reported a position in NVCR in Q4 2019 and has held it in 9 quarters since. The position peaked at $229K in Q1 2020. 317 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

Fieldpoint Private Securities held 801 shares of NovoCure worth $56K as of Q2 2022.
Fieldpoint Private Securities sold 2 NovoCure shares in Q2 2022, an estimated $151.
NovoCure made up 0.02% of Fieldpoint Private Securities's portfolio in Q2 2022, its #461 holding.
Fieldpoint Private Securities first reported a position in NovoCure in Q4 2019 and has held it in 9 quarters since.
Fieldpoint Private Securities's NovoCure position peaked at $229K in Q1 2020.
317 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.